Bayhill's BHT-3034 receives FDA IND clearance for treatment of Myasthenia gravis
01/03/2011 10:00
Bayhill's Therapeutics novel BHT-3034 vaccine immunotherapy has been cleared by FDA for treatment of patients with myasthenia gravis. For further information see: www.news-medical.net/news/20110301/Bayhills-BHT-3034-receives-FDA-IND-clearance-for-treatment-of-myasthenia-gravis.aspx